background
inflammatori
respons
pneumococc
infect
primarili
driven
immunoreact
bacteri
cell
wall
compon
lipoteicho
acid
lta
acut
releas
compon
occur
pneumococc
infect
treat
blactam
antibiot
object
hypothes
nonlyt
rifampicin
compar
lytic
blactam
antibiot
treatment
would
attenu
inflammatori
respons
patient
pneumococc
pneumonia
method
pristin
pneumonia
treat
rifampicin
attenu
inflamm
trial
random
therapeut
control
exploratori
studi
patient
communityacquir
pneumococc
pneumonia
look
lta
releas
inflammatori
clinic
respons
treatment
rifampicin
blactam
compar
treatment
blactam
antibiot
trial
regist
dutch
trial
registri
number
european
clinic
trial
databas
number
result
fortyon
patient
communityacquir
pneumonia
includ
pneumococc
pneumonia
lta
releas
ltamedi
inflammatori
respons
clinic
outcom
inflammatori
biomark
transcript
profil
differ
treatment
group
pristin
studi
demonstr
feasibl
ad
rifampicin
blactam
antibiot
treatment
communityacquir
pneumococc
pneumonia
despit
solid
vitro
experiment
anim
research
evid
fail
demonstr
differ
plasma
lta
concentr
subsequ
inflammatori
clinic
respons
like
inhibitori
effect
human
plasma
contribut
low
immun
respons
patient
addit
lta
plasma
concentr
could
low
mount
respons
via
tolllik
receptor
vitro
may
nonetheless
effect
vivo
host
inflammatori
respons
pneumococc
diseas
contribut
significantli
morbid
mortal
infect
gramposit
bacteria
inflammatori
respons
pneumococc
infect
primarili
driven
immunoreact
bacteri
cell
wall
compon
lipoteicho
acid
lta
releas
intracellular
protein
lta
recogn
tolllik
receptor
pattern
recognit
receptor
macrophag
bind
lta
induc
releas
proinflammatori
cytokin
eg
tnf
neutrophil
influx
bacteri
cell
wall
compon
releas
bacteria
kill
autolysi
host
immun
cell
import
determin
sever
inflamm
acut
breakdown
bacteri
cell
wall
occur
upon
exposur
blactam
antibiot
firstlin
treatment
pneumococc
infect
mani
guidelin
reduct
releas
bacteri
cell
wall
product
may
decreas
inflamm
reduc
tissu
damag
ultim
reduc
morbid
mortal
strategi
dampen
host
inflammatori
respons
studi
extens
current
dexamethason
adjunct
treatment
patient
pneumococc
mening
use
highincom
countri
diminish
inflammatori
respons
consequ
neurolog
sequela
communityacquir
pneumonia
macrolid
seem
immun
modulatori
effect
enhanc
antibacteri
effect
neutrophil
quash
immun
respons
bacteri
kill
howev
clinic
trial
blactam
monotherapi
noninferior
macrolid
blactam
combin
therapi
anoth
potenti
approach
kill
bacteria
without
immedi
lyse
thu
prevent
releas
proinflammatori
cell
wall
product
would
reduc
complet
inflammatori
trigger
interf
begin
inflamm
cascad
blactam
antibiot
disrupt
bacteri
cell
wall
caus
lysi
bacterium
subsequ
trigger
inflammatori
respons
nonlyt
antibiot
rifampicin
caus
much
less
inflamm
exampl
vitro
studi
shown
rifampicin
result
less
releas
lta
proinflammatori
compound
streptococcu
pneumonia
blactam
antibiot
ceftriaxon
meropenem
despit
similar
bacteri
kill
effect
furthermor
rifampicin
may
reduc
inflammatori
respons
downregul
express
proinflammatori
pattern
recognit
receptor
kill
pneumonia
commenc
instantli
therapeut
drug
concentr
achiev
therefor
rifampicininduc
nonlyt
kill
start
blactam
lytic
kill
although
anim
model
suggest
benefici
effect
rifamycin
reduct
inflamm
pneumococc
infect
data
human
avail
therefor
hypothes
nonlyt
rifampicin
compar
lytic
blactam
antibiot
treatment
would
attenu
inflammatori
respons
patient
pneumococc
pneumonia
shortli
start
treatment
pristin
pneumonia
treat
rifampicin
attenu
inflamm
trial
random
therapeut
control
exploratori
studi
patient
communityacquir
pneumonia
look
inflammatori
respons
treatment
rifampicin
blactam
compar
treatment
blactam
antibiot
studi
conduct
leiden
univers
medic
center
lumc
tertiari
univers
hospit
netherland
studi
approv
lumc
medic
ethic
committe
patient
provid
written
inform
consent
studi
perform
complianc
declar
helsinki
trial
regist
dutch
trial
registri
number
european
clinic
trial
databas
number
patient
recruit
emerg
depart
inclus
criteria
year
age
hospit
admiss
communityacquir
pneumonia
moder
sever
diseas
defin
confus
uraemia
elev
respiratori
rate
hypotens
age
year
older
score
one
risk
factor
pneumococc
pneumonia
ie
pleurit
chest
pain
acut
onset
symptom
cardiovascular
diseas
leucocyt
count
alveolar
pattern
lobar
segment
subsegment
infiltr
chest
xray
exclus
criteria
allergi
rifampicin
rifampicininduc
haemolyt
anaemia
thrombocytopenia
medic
histori
liver
failur
use
voriconazol
pi
pregnanc
breastfeed
patient
treat
accord
current
guidelin
netherland
includ
least
blactam
antibiot
sinc
resist
pneumonia
penicillin
extrem
rare
netherland
empir
therapi
usual
initi
benzylpenicillin
patient
random
intervent
group
control
group
use
prepar
singl
random
list
list
gener
studi
patient
assign
independ
person
sinc
blind
rifampicin
treatment
due
orang
secret
imposs
studi
open
label
intervent
group
treat
mg
rifampicin
intraven
h
combin
blactam
antibiot
rifampicin
given
blactam
antibiot
blactam
antibiot
treatment
ad
intervent
treatment
prescrib
current
guidelin
rifampicinresist
mutant
readili
appear
rifampicin
monotherapi
control
group
treat
blactam
antibiot
without
rifampicin
sever
communityacquir
pneumonia
score
patient
risk
factor
legionella
pneumonia
ciprofloxacin
ad
empir
treatment
patient
either
group
cover
legionella
infect
decis
total
treatment
durat
assign
treat
physician
accord
dutch
guidelin
clinic
respons
assess
research
team
use
time
clinic
stabil
score
monitor
time
defervesc
thirti
day
start
therapi
clinic
recoveri
assess
clinic
research
team
time
clinic
stabil
defin
day
admiss
temperatur
c
heart
rate
beat
per
min
respiratori
rate
per
min
oxygen
satur
systol
blood
pressur
mmhg
mental
statu
normal
abil
oral
intak
criteria
met
day
discharg
day
discharg
defin
day
clinic
stabil
time
defervesc
defin
bodi
temperatur
c
two
consecut
measur
least
h
apart
prescript
antipyret
part
studi
protocol
decis
discharg
patient
left
attend
physician
criteria
discharg
recoveri
patient
level
abl
take
care
abil
complet
minimum
day
cours
oral
antibiot
sputum
cultur
blood
cultur
nasopharyng
swab
viral
pcr
binaxnow
pneumococc
urinari
antigen
test
urinari
inhibit
multiplex
immunoassay
imia
detect
serotyp
pneumococci
perform
identifi
caus
agent
pneumococc
infect
defin
posit
sputum
blood
cultur
pneumonia
posit
binaxnow
imia
inclus
inclus
h
day
inclus
blood
sampl
taken
determin
respons
assay
biomark
inclus
h
day
inclus
blood
collect
paxgen
rna
tube
multiplex
ligationdepend
probe
amplif
mlpa
assess
inflammatori
respons
exploratori
studi
primari
outcom
feasibl
ad
rifampicin
blactam
antibiot
treatment
communityacquir
pneumococc
pneumonia
differ
lta
releas
patient
treat
intervent
group
versu
one
control
group
secondari
outcom
variabl
ltamedi
inflammatori
respons
clinic
respons
mlpa
result
inflammatori
biomark
laboratori
procedur
determin
lta
respons
ltamedi
inflammatori
respons
describ
supplementari
data
avail
jac
onlin
clinic
outcom
paramet
time
clinic
stabil
time
defervesc
inhospit
mortal
day
mortal
length
stay
hospit
icu
admiss
biomark
creactiv
protein
crp
procalcitonin
pct
midregion
proadrenomedullin
mrproadm
use
defin
inflammatori
respons
crp
measur
via
turbidimetr
reaction
antibodyantigen
complex
roch
v
r
mannheim
germani
catalogu
number
pct
mrproadm
determin
immunofluoresc
time
resolv
amplifi
cryptat
emiss
technolog
brahm
kryptor
v
r
hennigsdorf
germani
catalogu
number
pct
mrproadm
case
patient
discharg
blood
sampl
biomark
assess
stop
clinic
recoveri
assum
biomark
normal
compens
miss
valu
known
halfliv
biomark
appli
normal
valu
minimum
last
measur
sampl
crp
halflif
h
normal
valu
mgl
pct
h
normal
valu
ngml
mrproadm
h
normal
valu
nmoll
differ
biomark
defin
chang
valu
first
second
h
start
treatment
dualcolour
reversetranscriptas
mlpa
permit
accur
rna
express
profil
select
transcript
identifi
biomark
signatur
host
inflammatori
respons
infect
partial
leastsquar
discrimin
analysi
plsda
perform
identifi
compon
discrimin
group
timepoint
h
variabl
import
project
vip
score
measur
variabl
import
plsda
model
marker
highest
vip
score
best
discrimin
studi
exploratori
studi
determin
feasibl
ad
rifampicin
standard
antibiot
treatment
patient
acut
communityacquir
pneumonia
analysi
limit
descript
statist
statist
signific
group
sought
consequ
formal
power
calcul
done
continu
variabl
summar
either
mean
standard
deviat
median
iqr
student
ttest
mannwhitney
utest
use
appropri
categor
variabl
given
number
percentag
v
test
fisher
exact
test
use
hypothesi
test
model
effect
lta
releas
level
effect
biomark
time
differ
treatment
group
use
linear
mix
model
lmm
use
result
first
h
sampl
sinc
time
window
interest
follow
hypothesi
lta
releas
biomark
respons
start
treatment
assum
linear
relationship
therefor
use
polynomi
spline
model
trend
lta
releas
biomark
respons
chang
biomark
assess
compar
chang
within
first
second
h
treatment
student
ttest
statist
analys
perform
use
spss
ibm
softwar
version
januari
may
total
patient
communityacquir
pneumonia
includ
empir
start
antibiot
treatment
studi
patient
found
pneumococc
pneumonia
patient
intervent
group
control
group
patient
complet
h
four
dosag
rifampicin
treatment
receiv
three
dosag
receiv
two
dosag
median
number
infect
lobe
one
median
age
total
cohort
year
male
median
score
tabl
twentysix
patient
receiv
ciprofloxacin
empir
treatment
top
blactam
antibiot
without
rifampicin
sinc
group
small
differ
exist
treatment
group
baselin
characterist
outlin
tabl
tabl
avail
supplementari
data
jac
onlin
diagnosi
pneumococc
pneumonia
patient
base
posit
blood
cultur
patient
posit
sputum
cultur
patient
posit
binaxnow
antigen
test
patient
posit
imia
test
patient
variou
pneumonia
serotyp
detect
interestingli
two
patient
infect
involv
one
serotyp
tabl
short
lta
releas
could
demonstr
two
commerci
elisa
test
two
studi
patient
proven
pneumococc
pneumonia
pneumococc
bacteraemia
ltamedi
inflammatori
respons
via
detect
result
laboratori
work
lta
respons
ltamedi
inflammatori
respons
describ
supplementari
data
time
clinic
stabil
time
defervesc
patient
pneumococc
pneumonia
differ
significantli
treatment
group
figur
b
none
patient
pneumococc
pneumonia
die
hospit
within
day
day
overal
mortal
median
length
hospit
stay
day
signific
differ
icu
admiss
advers
event
recoveri
day
pneumococc
group
complet
cohort
clinic
outcom
paramet
describ
tabl
biomark
crp
pct
mrproadm
measur
variou
timepoint
start
treatment
figur
start
treatment
median
crp
mrproadm
valu
slightli
higher
rifampicin
intervent
group
wherea
median
pct
slightli
higher
group
treat
without
rifampicin
start
treatment
biomark
level
significantli
differ
group
lmm
figur
tabl
crp
valu
show
small
increas
within
first
h
start
treatment
treatment
group
figur
patient
pneumococc
pneumonia
biomark
show
steadi
declin
h
start
treatment
figur
chang
concentr
biomark
nonlyt
antibiot
treatment
effect
inflamm
cap
patient
one
caus
agent
detect
groeneveld
et
al
differ
group
first
second
h
start
treatment
tabl
tabl
four
patient
blood
sampl
n
limit
taken
hospit
inclus
h
day
inclus
rna
express
profil
transcript
perform
mlpa
heat
map
show
colour
quantiti
variou
transcript
figur
patient
similar
transcript
profil
plot
adjac
although
nine
patient
pneumococc
pneumonia
rifampicin
cluster
togeth
gene
express
data
reveal
clear
pattern
associ
treatment
diseas
statu
identifi
transcript
highest
discriminatori
power
pneumococc
versu
infect
plsda
run
vip
score
calcul
transcript
five
highest
vip
score
shown
figur
chemokin
cc
motif
ligand
statist
signific
lower
h
start
treatment
patient
pneumococc
pneumonia
versu
patient
nonpneumococc
pneumonia
treatment
without
rifampicin
significantli
affect
result
pristin
studi
first
exploratori
clinic
trial
human
determin
feasibl
ad
rifampicin
standard
treatment
blactam
patient
communityacquir
pneumococc
pneumonia
rifampicin
ad
reduc
releas
bacteri
compound
within
first
hour
therapi
therebi
attenu
inflammatori
respons
initi
small
group
blactam
antibiot
addit
nonlyt
rifampicin
antibiot
versu
lytic
blactam
antibiot
treatment
pneumococc
pneumonia
reveal
differ
blood
concentr
variou
inflammatori
biomark
clinic
respons
treatment
strength
studi
high
percentag
pneumococc
infect
includ
frequent
sequenti
measur
spectrum
biomark
first
h
assess
hypothesi
complet
biomark
profil
use
evalu
specif
inflammatori
respons
initi
includ
patient
high
sever
score
percentag
pneumococc
infect
highest
group
high
sever
would
best
contrast
possibl
effect
inclus
eighth
nonlyt
antibiot
treatment
effect
inflamm
cap
jac
studi
patient
extend
inclus
criteria
patient
specif
risk
factor
pneumococc
pneumonia
speed
inclus
appli
extens
test
pneumococc
infect
ensur
identif
patient
pneumococc
pneumonia
abl
confirm
pneumococc
infect
patient
percentag
higher
compar
hospit
intens
care
studi
communityacquir
pneumonia
vitro
studi
anim
model
demonstr
differ
lta
releas
inflammatori
respons
within
hour
lytic
versu
nonlyt
antibiot
treatment
pneumonia
although
extens
sampl
challeng
human
trial
essenti
test
hypothesi
therefor
larg
number
sequenti
sampl
collect
import
strength
studi
extens
sampl
detect
express
significantli
differ
pneumococc
pneumonia
versu
nonpneumococc
pneumonia
h
start
treatment
known
upregul
pneumococc
infect
essenti
chemokin
pneumococc
adapt
immun
find
need
valid
larger
cohort
pneumonia
patient
weak
pilot
trial
small
sampl
size
line
exploratori
charact
studi
anticip
lta
biomark
respons
induc
blactam
treatment
would
spread
across
broad
rang
includ
patient
rifampicin
ad
blactam
treatment
blactam
treatment
random
ratio
four
patient
pneumococc
pneumonia
treat
blactam
therapi
assumpt
imperfect
small
group
hinder
comparison
exampl
analys
biomark
inflamm
start
treatment
pct
valu
seem
higher
blactam
group
crp
mrproadm
higher
rifampicin
group
sinc
three
sampl
one
sampl
miss
avail
blactam
group
interpret
find
difficult
could
detect
lta
plasma
direct
inflammatori
respons
via
lta
cell
wall
compon
bind
induc
releas
broad
rang
proinflammatori
cytokin
lead
neutrophilmedi
lung
damag
morbid
mortal
like
inhibitori
effect
human
plasma
contribut
low
immun
respons
patient
addit
median
number
one
infect
lung
lobe
repres
rel
limit
pneumococc
load
lta
plasma
concentr
could
low
mount
respons
via
vitro
see
supplementari
data
may
nonetheless
effect
vivo
lta
releas
may
also
delay
quinolon
treatment
ciprofloxacin
frequent
coadminist
cohort
delay
lta
releas
may
decreas
potenti
differ
inflammatori
respons
two
treatment
group
group
without
rifampicin
baselin
compar
groeneveld
et
al
final
anoth
reason
absenc
detect
lta
sampl
could
serotyp
caus
pneumococc
pneumonia
differ
pneumococc
isol
differ
lytic
effect
experiment
mening
model
rabbit
serotyp
caus
lta
releas
inflamm
pneumococc
serotyp
studi
one
patient
pneumococc
pneumonia
serotyp
versu
four
patient
serotyp
contrast
lta
plasma
lta
detect
site
infect
human
see
supplementari
data
exampl
liquor
patient
pneumococc
mening
lta
detect
day
start
treatment
possibl
punctur
infect
lung
lobe
repeat
measur
critic
ill
human
patient
therefor
human
studi
determin
lta
load
lung
pneumonia
perform
previou
vitro
anim
studi
shown
vast
differ
lta
releas
inflammatori
respons
lytic
versu
nonlyt
antibiot
treatment
potenti
clinic
benefit
decreas
lta
releas
inflammatori
respons
patient
pneumococc
pneumonia
might
substanti
restrepo
et
al
demonstr
patient
communityacquir
pneumonia
immedi
transfer
icu
emerg
depart
better
patient
initi
treat
ward
thereaft
transfer
icu
secondari
deterior
could
caus
inflamm
due
lta
releas
start
treatment
larg
random
trial
patient
gramposit
staphylococcu
aureu
bacteraemia
show
adjunct
clinic
benefit
rifampicin
standard
often
flucloxacillin
antibiot
treatment
longterm
endpoint
trial
use
make
comparison
shortterm
outcom
measur
difficult
strategi
dampen
inflammatori
respons
pneumonia
far
primarili
focus
corticosteroid
corticosteroid
therapi
demonstr
result
shorter
time
clinic
stabil
limit
shorten
hospit
stay
patient
nonsever
communityacquir
pneumonia
studi
adult
sever
diseas
shown
reduct
mortal
qualiti
studi
moder
studi
corticosteroid
therapi
increas
risk
hyperglycemia
therefor
corticosteroid
includ
current
treatment
guidelin
altern
therapeut
option
explor
attenu
inflamm
effect
benefit
nonlyt
antibiot
treatment
pneumococc
infect
may
easier
detect
prove
pneumococc
mening
patient
group
patient
high
morbid
longterm
sequela
substanti
mortal
strategi
improv
outcom
urgent
need
moreov
clinic
result
studi
could
blur
use
antipyret
higher
lta
concentr
liquor
human
patient
pneumococc
mening
associ
wors
outcom
addit
rabbit
pneumococc
mening
rifampicin
reduc
lta
releas
inflammatori
respons
substanti
improv
surviv
therefor
clinic
trial
nonlyt
antibiot
pneumococc
mening
develop
rifampicin
would
antibiot
choic
sinc
effect
kill
pneumonia
caus
least
releas
lta
per
kill
bacteri
cell
unfortun
could
compar
monotherapi
nonlyt
rifampicin
antibiot
versu
monotherapi
lytic
blactam
antibiot
would
highli
relev
differ
research
question
reason
current
dutch
guidelin
communityacquir
pneumonia
recommend
blactam
antibiot
eg
benzylpenicillin
treatment
fact
rifampicin
monotherapi
may
induc
resist
treatment
therefor
would
uneth
withhold
firstlin
treatment
patient
communityacquir
pneumonia
signific
differ
lta
releas
demonstr
rabbit
model
pneumonia
mening
compar
blactam
monotherapi
rifampicin
follow
blactam
antibiot
therapi
h
later
rifampicin
treatment
group
studi
rifampicin
frequent
given
blactam
treatment
median
time
frame
min
iqr
min
therefor
antimicrobi
kill
pneumonia
group
might
primarili
caus
blactam
lytic
kill
effect
conclus
pristin
exploratori
studi
demonstr
feasibl
ad
rifampicin
blactam
antibiot
nonlyt
antibiot
treatment
effect
inflamm
cap
jac
treatment
communityacquir
pneumococc
pneumonia
howev
despit
solid
vitro
experiment
anim
research
evid
fail
demonstr
differ
lta
subsequ
inflammatori
respons
studi
select
group
patient
pneumococc
mening
necessari
confirm
hypothesi
nonlyt
antibiot
treatment
attenu
inflammatori
respons
improv
clinic
outcom
groeneveld
et
al
